Bio News

TharSUS will acquire Alkeus for $450 million (approximately 640 billion won). TharSUS will pay $270 million in cash (approximately 384 billion won) and $180 million in common stock (approximately 256 billion won). TharSUS plans to obtain clinical results for the Phase 3 investigational drug gildeuretinol in 2029.

BIOBOOK TEAM
biobookmedia@biobook.co.krCosentyx Approved by FDA for 11th Indication: Polymyalgia Rheumatica
Delonix and Singapore’s A*STAR IDL to Collaborate on Vaccine Against Drug-Resistant Klebsiella pneumoniae
Brazilian Health Regulatory Agency Approves Oral Plaque Psoriasis Treatment Icotyde
Medtronic to Acquire Contego Medical for $380 Million
Brazilian Health Regulatory Agency Approves Botox for Masseter Muscle Prominence
Roche’s oral SERD Itovebi wins FDA approval, cutting risk of progression by 62%